Project NISCI – Antibodies Against Nogo-A to Enhance Plasticity, Regeneration and Functional Recovery After Spinal Cord…

Basic data

Acronym:
NISCI
Title:
Antibodies Against Nogo-A to Enhance Plasticity, Regeneration and Functional Recovery After Spinal Cord Injury - A Multicenter International Randomized Double Blind Placebo Controlled Phase II Clinical Proof of Concept Trial
Duration:
15/05/2019 to 31/12/2023
Abstract / short description:
NISCI (Nogo-A Inhibition in acute Spinal Cord Injury) is a multicenter, multinational, placebo controlled phase-II study for the safety and preliminary efficacy of intrathecal anti-Nogo-A [NG101] in patients with acute cervical spinal cord injury. The purpose of the NISCI trial is to test if an antibody therapy can improve motor function and quality of life of tetraplegic patients. A previous trial showed this treatment is safe and well accepted. The study has 3 phases: screening/baseline phase, treatment phase, and a follow-up phase.
The study design will allow simultaneous enrolment of patients with complete or incomplete SCI. Enrolment and stratification of the patients is based and individualized prediction of upper limb outcomes.
This current trial has been approved by the National Ethics Committee and Ministry of Health for all participating trial sites.
For further information please visit NISCI website: https://nisci-2020.eu
Keywords:
Spinal Cord Injuries
Tetraplegia
Upper limbs function

Involved staff

Managers

Faculty of Medicine
University of Tübingen

Contact persons

Faculty of Medicine
University of Tübingen
Casualty Hospital (Tübingen) (BGU)
Associated institutes

Other staff

Universität Tübingen

Local organizational units

Casualty Hospital (Tübingen) (BGU)
Associated institutes
University of Tübingen

Funders

Heidelberg, Baden-Württemberg, Germany
Help

will be deleted permanently. This cannot be undone.